AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Mesoblast shares have risen by 65% in the past month.
- FDA approval for its stem-cell therapy Ryoncil is expected soon.
- Mesoblast is advancing six programs in phase III clinical trials.
Mesoblast Limited (ASX:MSB), a leader in stem-cell therapies, has seen a significant surge in its share price, climbing 65% over the past month. This rise reflects growing investor confidence in the company’s potential, driven by expectations that the US Food & Drug Administration (FDA) will soon approve its therapy, Ryoncil, for pediatric steroid-resistant graft-versus-host disease (GvHD).
Anticipation Builds Around FDA Approval
Mesoblast’s founder and CEO, Silviu Itescu, has expressed optimism that the FDA will approve Ryoncil “no later than the first week of January, and possibly sooner.” If successful, this would represent a major milestone for the company, which has faced multiple setbacks with US regulatory approvals in the past. To date, Mesoblast's only approved drug is available in Japan, also for GvHD.
Ryoncil, an allogeneic stem-cell therapy, is derived from healthy human donor cells and can be mass-produced for use when needed. This contrasts with treatments using a patient's own cells, which are typically more complex and time-consuming to develop. If approved, Ryoncil would mark the first time the FDA has given the green light to an allogeneic stem cell treatment, a significant achievement for both the company and the field of regenerative medicine.
Mesoblast’s Expanding Pipeline
Mesoblast has no fewer than six therapies in phase III clinical trials, targeting a range of conditions beyond GvHD. These include treatments for adult GvHD, heart failure, chronic lower back pain, inflammatory bowel disease/Crohn’s disease, and childhood hypoplastic left-heart syndrome. According to Itescu, the approval of Ryoncil could pave the way for the company to pursue additional indications across these programs, further expanding its market reach.
The company has also received encouraging feedback from the FDA following an inspection and approval of its manufacturing plant in Singapore. This has bolstered confidence in the company's readiness to launch Ryoncil upon approval.
GvHD and Market Potential
GvHD, a condition resulting from bone marrow transplants where the donor tissue rejects the patient’s body, affects thousands of patients each year. Around 30,000 bone marrow transplants are performed annually, half of them in the US, with pediatric patients making up about 20% of this group. The condition has high mortality rates, and current treatments, such as steroids, often fail to provide a solution. Should Ryoncil gain approval, it would offer a critical new option for these vulnerable patients.
While Mesoblast shares are currently trading at $1.52, still far from their 2011 peak of $9.50, the company's growing pipeline and potential FDA approval position it as a key player in the regenerative medicine space.
With a promising range of therapies and an expected breakthrough in the US market, Mesoblast is moving toward a transformative period in its development. The anticipated FDA approval for Ryoncil could mark a turning point for the company, opening the door to wider applications and further growth.
